Hepatitis C pharmacogenetics: state of the art in 2010.


Journal Article (Review)

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

Full Text

Cited Authors

  • Afdhal, NH; McHutchison, JG; Zeuzem, S; Mangia, A; Pawlotsky, J-M; Murray, JS; Shianna, KV; Tanaka, Y; Thomas, DL; Booth, DR; Goldstein, DB; Pharmacogenetics and Hepatitis C Meeting Participants,

Published Date

  • January 2011

Published In

Volume / Issue

  • 53 / 1

Start / End Page

  • 336 - 345

PubMed ID

  • 21254181

Pubmed Central ID

  • 21254181

Electronic International Standard Serial Number (EISSN)

  • 1527-3350

International Standard Serial Number (ISSN)

  • 0270-9139

Digital Object Identifier (DOI)

  • 10.1002/hep.24052


  • eng